Home
About
Overview
Sharing Data
ORCID
Help
History (6)
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500?mg/m(2) every 21 days in patients with cancer.
PTEN loss in the Myf5 lineage redistributes body fat and reveals subsets of white adipocytes that arise from Myf5 precursors.
RNA Processing, Post-Transcriptional
Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.
Measuring tumor mutation burden in cell-free DNA: advantages and limits.
See All 6 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Measuring tumor mutation burden in cell-free DNA: advantages and limits.
Addeo A, Weiss GJ. Measuring tumor mutation burden in cell-free DNA: advantages and limits. Transl Lung Cancer Res. 2019 Aug; 8(4):553-555.
View in:
PubMed
authors with profiles
Glen Weiss MD, MBA